Analyst Ratings For ProMetic Life Sciences (TSE:PLI)
Today, Scotiabank reiterated its Outperform rating on ProMetic Life Sciences (TSE:PLI) with a price target of C$4.75.
There are 2 hold ratings, 4 buy ratings on the stock.
The current consensus rating on ProMetic Life Sciences (TSE:PLI) is Buy (Score: 2.67) with a consensus target price of C$4.63 per share, a potential .
Some recent analyst ratings include
- 4/19/2017-Scotiabank Reiterated Rating of Outperform.
- 4/19/2017-Royal Bank of Canada Reiterated Rating of Outperform.
- 10/13/2016-Bloom Burton Reiterated Rating of Hold.
- 5/26/2016-National Bank Financial Reiterated Rating of Outperform.
About ProMetic Life Sciences (TSE:PLI)
Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs. ProMetic is also developing its own small molecule therapeutic products targeting unmet medical needs in the field of fibrosis, autoimmune disease/inflammation and cancer. It has research and development facilities in the United Kingdom, the United States and Canada; manufacturing facilities in the Isle of Man and Canada, and business development activities in the United States, Europe and Asia.
Recent Trading Activity for ProMetic Life Sciences (TSE:PLI)
Shares of ProMetic Life Sciences closed the previous trading session at 2.09 down -0.01 -0.48% with 535,332 shares trading hands.